Despite encouraging clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant opposition from managed care entities. Such insurers are frequently erecting obstacles to coverage, like high cost requirements and prior autho